Exosomes: Potential for early detection in pancreatic cancer

Future Oncology

Volumn 12, Issue 8, 2016, Pages 1081-1090

  Lu, Lingeng ^a   Risch, Harvey A ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

biomarkers; early detection; exosomes; pancreatic cancer

Indexed keywords

BODY FLUID; CANCER CELL; CANCER DIAGNOSIS; CANCER PROGNOSIS; CELL MIGRATION; DENSITY GRADIENT CENTRIFUGATION; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ELECTRON MICROSCOPY; EXOSOME; GENE MUTATION; HUMAN; KUPFFER CELL; NONHUMAN; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; SENSITIVITY AND SPECIFICITY; TUMOR MICROENVIRONMENT; EARLY CANCER DIAGNOSIS; GENETICS; METABOLISM; PANCREATIC NEOPLASMS; PROCEDURES;

BIOLOGICAL MARKER; MICRORNA;

BIOMARKERS; EARLY DETECTION OF CANCER; EXOSOMES; HUMANS; MICRORNAS; PANCREATIC NEOPLASMS; PROTEOMICS;

EID: 84961879679     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon-2015-0005     Document Type: Review

References (121)

1. Van Niel G, Porto-Carreiro I, Simoes S, Raposo G. Exosomes: A common pathway for a specialized function. J. Biochem. 140(1), 13-21 (2006).
2. Thery C, Regnault A, Garin J et al. Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the heat shock protein HSC73. J. Cell Biol. 147(3), 599-610 (1999).
3. Raposo G, Nijman HW, Stoorvogel W et al. B lymphocytes secrete antigen-presenting vesicles. J. Exp. Med. 183(3), 1161-1172 (1996).
4. Blanchard N, Lankar D, Faure F et al. TCR activation of human T cells induces the production of exosomes bearing the TCR/CD3/zeta complex. J. Immunol. 168(7), 3235-3241 (2002).
5. Raposo G, Tenza D, Mecheri S, Peronet R, Bonnerot C, Desaymard C. Accumulation of major histocompatibility complex class II molecules in mast cell secretory granules and their release upon degranulation. Mol. Biol. Cell 8(12), 2631-2645 (1997).
6. Van Niel G, Raposo G, Candalh C et al. Intestinal epithelial cells secrete exosome-like vesicles. Gastroenterology 121(2), 337-349 (2001).
7. Mears R, Craven RA, Hanrahan S et al. Proteomic analysis of melanoma-derived exosomes by two-dimensional polyacrylamide gel electrophoresis and mass spectrometry. Proteomics 4(12), 4019-4031 (2004).
8. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 9(6), 654-659 (2007).
9. Ramachandran S, Palanisamy V. Horizontal transfer of RNAs: exosomes as mediators of intercellular communication. Wiley Interdiscip. Rev. RNA 3(2), 286-293 (2012).
10. Skog J, Wurdinger T, Van Rijn S et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat. Cell Biol. 10(12), 1470-1476 (2008).
11. Smalheiser NR. Exosomal transfer of proteins and RNAs at synapses in the nervous system. Biol. Direct 2, 35 (2007).
12. Eldh M, Ekstrom K, Valadi H et al. Exosomes communicate protective messages during oxidative stress; possible role of exosomal shuttle RNA. PLoS ONE 5(12), e15353 (2010).
13. Zhang HG, Grizzle WE. Exosomes and cancer: A newly described pathway of immune suppression. Clin. Cancer. Res. 17(5), 959-964 (2011).
14. Whiteside TL. Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes). Biochem. Soc. Trans. 41(1), 245-251 (2013).
15. Sceneay J, Smyth MJ, Moller A. The pre-metastatic niche: finding common ground. Cancer Metastasis Rev. 32(3-4), 449-464 (2013).
16. Psaila B, Lyden D. The metastatic niche: adapting the foreign soil. Nat. Rev. Cancer 9(4), 285-293 (2009).
17. Dutta S, Warshall C, Bandyopadhyay C, Dutta D, Chandran B. Interactions between exosomes from breast cancer cells and primary mammary epithelial cells leads to generation of reactive oxygen species which induce DNA damage response, stabilization of p53 and autophagy in epithelial cells. PLoS ONE 9(5), e97580 (2014).
18. Meckes DG Jr., Raab-Traub N. Microvesicles and viral infection. J. Virol. 85(24), 12844-12854 (2011).
19. Azmi AS, Bao B, Sarkar FH. Exosomes in cancer development, metastasis, and drug resistance: A comprehensive review. Cancer Metastasis Rev. 32(3-4), 623-642 (2013).
20. Keerthikumar S, Chisanga D, Ariyaratne D et al. ExoCarta: A web-based compendium of exosomal cargo. J. Mol. Biol. doi:10.1016/j. jmb.2015.09.019 (2015) (Epub ahead of print).
21. Batista BS, Eng WS, Pilobello KT, Hendricks-Munoz KD, Mahal LK. Identification of a conserved glycan signature for microvesicles. J. Proteome Res. 10(10), 4624-4633 (2011).
22. Mathivanan S, Ji H, Simpson RJ. Exosomes: extracellular organelles important in intercellular communication. J. Proteomics 73(10), 1907-1920 (2010).
23. Zoller M. Pancreatic cancer diagnosis by free and exosomal miRNA. World J. Gastrointest. Pathophysiol. 4(4), 74-90 (2013).
24. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J. Clin. 65(1), 5-29 (2015).
25. Risch HA. Pancreatic cancer: Helicobacter pylori colonization, N-nitrosamine exposures, and ABO blood group. Mol. Carcinog. 51(1), 109-118 (2012).
26. Gong Z, Holly EA, Bracci PM. Survival in population-based pancreatic cancer patients: San Francisco Bay area, 1995-1999. Am. J. Epidemiol. 174(12), 1373-1381 (2011).
27. Ghaneh P, Costello E, Neoptolemos JP. Biology and management of pancreatic cancer. Gut 56(8), 1134-1152 (2007).
28. Werner J, Combs SE, Springfeld C, Hartwig W, Hackert T, Buchler MW. Advanced-stage pancreatic cancer: therapy options. Nat. Rev. Clin. Oncol. 10(6), 323-333 (2013).
29. National Cancer Institute. General information about pancreatic cancer (2014). www.cancer.gov
30. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 20(10), 1218-1249 (2006).
31. Pitt HA. Curative treatment for pancreatic neoplasms. standard resection. Surg. Clin. North Am. 75(5), 891-904 (1995).
32. American Gastroenterological Association. American Gastroenterological Association medical position statement: epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. Gastroenterology 117(6), 1463-1484 (1999).
33. Giovinazzo F, Turri G, Zanini S, Butturini G, Scarpa A, Bassi C. Clinical implications of biological markers in pancreatic ductal adenocarcinoma. Surg. Oncol. 21(4), e171-e182 (2012).
34. Kaur S, Baine MJ, Jain M, Sasson AR, Batra SK. Early diagnosis of pancreatic cancer: challenges and new developments. Biomark. Med. 6(5), 597-612 (2012).
35. Guo J, Wang W, Liao P et al. Identification of serum biomarkers for pancreatic adenocarcinoma by proteomic analysis. Cancer Sci. 100(12), 2292-2301 (2009).
36. Hidalgo M. Pancreatic cancer. N. Engl. J. Med. 362(17), 1605-1617 (2010).
37. Brenner DJ, Hall EJ. Computed tomography-an increasing source of radiation exposure. N. Engl. J. Med. 357(22), 2277-2284 (2007).
38. Sahani DV, Shah ZK, Catalano OA, Boland GW, Brugge WR. Radiology of pancreatic adenocarcinoma: current status of imaging. J. Gastroenterol. Hepatol. 23(1), 23-33 (2008).
39. Kelly KA, Hollingsworth MA, Brand RE et al. Advances in Biomedical imaging, bioengineering, and related technologies for the development of biomarkers of pancreatic disease: summary of a National Institute of Diabetes and Digestive and Kidney Diseases and National Institute of Biomedical Imaging and Bioengineering Workshop. Pancreas 44(8), 1185-1194 (2015).
40. Schultz NA, Dehlendorff C, Jensen BV et al. MicroRNA biomarkers in whole blood for detection of pancreatic cancer. JAMA 311(4), 392-404 (2014).
41. Wang Y, Gu J, Roth JA et al. Pathway-based serum microRNA profiling and survival in patients with advanced stage non-small cell lung cancer. Cancer Res. 73(15), 4801-4809 (2013).
42. Wittmann J, Jack HM. Serum microRNAs as powerful cancer biomarkers. Biochim. Biophys. Acta 1806(2), 200-207 (2010).
43. Li A, Yu J, Kim H et al. MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls. Clin. Cancer. Res. 19(13), 3600-3610 (2013).
44. Allegra A, Alonci A, Campo S et al. Circulating microRNAs: new biomarkers in diagnosis, prognosis and treatment of cancer (review). Int. J. Oncol. 41(6), 1897-1912 (2012).
45. Riches A, Campbell E, Borger E, Powis S. Regulation of exosome release from mammary epithelial and breast cancer cells-A new regulatory pathway. Eur. J. Cancer 50(5), 1025-1034 (2014).
46. Zech D, Rana S, Buchler MW, Zoller M. Tumor-exosomes and leukocyte activation: an ambivalent crosstalk. Cell Commun Signal 10(1), 37 (2012).
47. Lasser C. Identification and analysis of circulating exosomal microRNA in human body fluids. Methods Mol. Biol. 1024, 109-128 (2013).
48. Lee TH, D'asti E, Magnus N, Al-Nedawi K, Meehan B, Rak J. Microvesicles as mediators of intercellular communication in cancer-The emerging science of cellular 'debris'. Semin. Immunopathol. 33(5), 455-467 (2011).
49. Inal JM, Kosgodage U, Azam S, Stratton D, Antwi-Baffour S, Lange S. Blood/plasma secretome and microvesicles. Biochim. Biophys. Acta 1834(11), 2317-2325 (2013).
50. Shao H, Chung J, Balaj L et al. Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nat. Med. 18(12), 1835-1840 (2012).
51. Parolini I, Federici C, Raggi C et al. Microenvironmental pH is a key factor for exosome traffic in tumor cells. J. Biol. Chem. 284(49), 34211-34222 (2009).
52. Smyth TJ, Redzic JS, Graner MW, Anchordoquy TJ. Examination of the specificity of tumor cell derived exosomes with tumor cells in vitro. Biochim. Biophys. Acta 1838, 2954-2965 (2014).
53. Ohno S, Takanashi M, Sudo K et al. Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol. Ther. 21(1), 185-191 (2013).
54. Tickner JA, Urquhart AJ, Stephenson SA, Richard DJ, O'Byrne KJ. Functions and therapeutic roles of exosomes in cancer. Front. Oncol. 4, 127 (2014).
55. Wendler F, Bota-Rabassedas N, Franch-Marro X. Cancer becomes wasteful: emerging roles of exosomes in cell-fate determination. J. Extracell. Vesicles doi:10.3402/jev. v2i0.22390 (2013) (Epub ahead of print).
56. Klein-Scory S, Tehrani MM, Eilert-Micus C et al. New insights in the composition of extracellular vesicles from pancreatic cancer cells: implications for biomarkers and functions. Proteome Sci. 12(1), 50 (2014).
57. Kowal J, Tkach M, Thery C. Biogenesis and secretion of exosomes. Curr. Opin. Cell Biol. 29, 116-125 (2014).
58. Stenmark H. Rab GTPases as coordinators of vesicle traffic. Nat. Rev. Mol. Cell Biol. 10(8), 513-525 (2009).
59. Wang Q, Ni Q, Wang X, Zhu H, Wang Z, Huang J. High expression of RAB27A and TP53 in pancreatic cancer predicts poor survival. Med. Oncol. 32(1), 372 (2015).
60. Shin SJ, Smith JA, Rezniczek GA et al. Unexpected gain of function for the scaffolding protein plectin due to mislocalization in pancreatic cancer. Proc. Natl Acad. Sci. USA 110(48), 19414-19419 (2013).
61. Colombo M, Moita C, Van Niel G et al. Analysis of ESCRT functions in exosome biogenesis, composition and secretion highlights the heterogeneity of extracellular vesicles. J. Cell Sci. 126(Pt 24), 5553-5565 (2013).
62. Baietti MF, Zhang Z, Mortier E et al. Syndecan-syntenin-ALIX regulates the biogenesis of exosomes. Nat. Cell Biol. 14(7), 677-685 (2012).
63. Chitadze G, Lettau M, Bhat J et al. Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17. Int. J. Cancer 133(7), 1557-1566 (2013).
64. Wang H, Rana S, Giese N, Buchler MW, Zoller M. Tspan8, CD44v6 and alpha6beta4 are biomarkers of migrating pancreatic cancer-initiating cells. Int. J. Cancer 133(2), 416-426 (2013).
65. Adamczyk KA, Klein-Scory S, Tehrani MM et al. Characterization of soluble and exosomal forms of the EGFR released from pancreatic cancer cells. Life Sci. 89(9-10), 304-312 (2011).
66. Javeed N, Sagar G, Dutta SK et al. Pancreatic cancer-derived exosomes causes paraneoplastic beta-cell dysfunction. Clin. Cancer Res. 21(7), 1722-1733 (2014).
67. Costa-Silva B, Aiello NM, Ocean AJ et al. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat. Cell Biol. 17(6), 816-826 (2015).
68. Kogure T, Lin WL, Yan IK, Braconi C, Patel T. Intercellular nanovesicle-mediated microRNA transfer: A mechanism of environmental modulation of hepatocellular cancer cell growth. Hepatology 54(4), 1237-1248 (2011).
69. Kosaka N, Iguchi H, Hagiwara K, Yoshioka Y, Takeshita F, Ochiya T. Neutral sphingomyelinase 2 (nSMase2)-dependent exosomal transfer of angiogenic microRNAs regulate cancer cell metastasis. J. Biol. Chem. 288(15), 10849-10859 (2013).
70. Cui H, Seubert B, Stahl E et al. Tissue inhibitor of metalloproteinases-1 induces a pro-tumourigenic increase of miR-210 in lung adenocarcinoma cells and their exosomes. Oncogene 34(28), 3640-3650 (2015).
71. Yamada N, Nakagawa Y, Tsujimura N et al. Role of intracellular and extracellular microRNA-92a in colorectal cancer. Transl. Oncol. 6(4), 482-492 (2013).
72. Tadokoro H, Umezu T, Ohyashiki K, Hirano T, Ohyashiki JH. Exosomes derived from hypoxic leukemia cells enhance tube formation in endothelial cells. J. Biol. Chem. 288(48), 34343-34351 (2013).
73. Bruno S, Collino F, Deregibus MC, Grange C, Tetta C, Camussi G. Microvesicles derived from human bone marrow mesenchymal stem cells inhibit tumor growth. Stem Cells Dev. 22(5), 758-771 (2013).
74. Bruno S, Grange C, Collino F et al. Microvesicles derived from mesenchymal stem cells enhance survival in a lethal model of acute kidney injury. PLoS ONE 7(3), e33115 (2012).
75. Rana S, Yue S, Stadel D, Zoller M. Toward tailored exosomes: The exosomal tetraspanin web contributes to target cell selection. Int. J. Biochem. Cell Biol. 44(9), 1574-1584 (2012).
76. Zhou M, Chen J, Zhou L, Chen W, Ding G, Cao L. Pancreatic cancer derived exosomes regulate the expression of TLR4 in dendritic cells via miR-203. Cell. Immunol. 292(1-2), 65-69 (2014).
77. Ding G, Zhou L, Qian Y et al. Pancreatic cancer-derived exosomes transfer miRNAs to dendritic cells and inhibit RFXAP expression via miR-212-3p. Oncotarget 6(30), 29877-29888 (2015).
78. Pai P, Rachagani S, Are C, Batra SK. Prospects of miRNA-based therapy for pancreatic cancer. Curr. Drug Targets 14(10), 1101-1109 (2013).
79. Drakaki A, Iliopoulos D. MicroRNA-gene signaling pathways in pancreatic cancer. Biomed. J. 36(5), 200-208 (2013).
80. Lubezky N, Loewenstein S, Ben-Haim M et al. MicroRNA expression signatures in intraductal papillary mucinous neoplasm of the pancreas. Surgery 153(5), 663-672 (2013).
81. Collins AL, Wojcik S, Liu J et al. A differential microRNA profile distinguishes cholangiocarcinoma from pancreatic adenocarcinoma. Ann. Surg. Oncol. 21(1), 133-138 (2014).
82. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol. Oncol. 110(1), 13-21 (2008).
83. Rabinowits G, Gercel-Taylor C, Day JM, Taylor DD, Kloecker GH. Exosomal microRNA: A diagnostic marker for lung cancer. Clin. Lung Cancer 10(1), 42-46 (2009).
84. Aushev VN, Zborovskaya IB, Laktionov KK et al. Comparisons of microRNA patterns in plasma before and after tumor removal reveal new biomarkers of lung squamous cell carcinoma. PLoS ONE 8(10), e78649 (2013).
85. Bryant RJ, Pawlowski T, Catto JW et al. Changes in circulating microRNA levels associated with prostate cancer. Br. J. Cancer 106(4), 768-774 (2012).
86. Tanaka Y, Kamohara H, Kinoshita K et al. Clinical impact of serum exosomal microRNA-21 as a clinical biomarker in human esophageal squamous cell carcinoma. Cancer 119(6), 1159-1167 (2013).
87. Lau C, Kim Y, Chia D et al. Role of pancreatic cancer-derived exosomes in salivary biomarker development. J. Biol. Chem. 288(37), 26888-26897 (2013).
88. Que R, Ding G, Chen J, Cao L. Analysis of serum exosomal microRNAs and clinicopathologic features of patients with pancreatic adenocarcinoma. World J. Surg. Oncol. 11, 219 (2013).
89. Madhavan B, Yue S, Galli U et al. Combined evaluation of a panel of protein and miRNA serum-exosome biomarkers for pancreatic cancer diagnosis increases sensitivity and specificity. Int. J. Cancer 136(11), 2616-2627 (2015).
90. Joshi GK, Deitz-Mcelyea S, Liyanage T et al. Label-Free nanoplasmonic-based short noncoding RNA sensing at attomolar concentrations allows for quantitative and highly specific assay of microRNA-10b in biological fluids and circulating exosomes. ACS Nano 9(11), 11075-11089 (2015).
91. Melo SA, Luecke LB, Kahlert C et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature 523(7559), 177-182 (2015).
92. San Lucas FA, Allenson K, Bernard V et al. Minimally invasive genomic and transcriptomic profiling of visceral cancers by next-generation sequencing of circulating exosomes. Ann. Oncol. doi:10.1093/annonc/mdv604 (2015) (Epub ahead of print).
93. Aikawa T, Whipple CA, Lopez ME et al. Glypican-1 modulates the angiogenic and metastatic potential of human and mouse cancer cells. J. Clin. Invest. 118(1), 89-99 (2008).
94. Kleeff J, Ishiwata T, Kumbasar A et al. The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. J. Clin. Invest. 102(9), 1662-1673 (1998).
95. Whipple CA, Young AL, Korc M. A KrasG12D-driven genetic mouse model of pancreatic cancer requires glypican-1 for efficient proliferation and angiogenesis. Oncogene 31(20), 2535-2544 (2012).
96. Kayed H, Kleeff J, Keleg S et al. Correlation of glypican-1 expression with TGF-beta, BMP, and activin receptors in pancreatic ductal adenocarcinoma. Int. J. Oncol. 29(5), 1139-1148 (2006).
97. Witkiewicz AK, Mcmillan EA, Balaji U et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat. Commun. 6, 6744 (2015).
98. Viale A, Pettazzoni P, Lyssiotis CA et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature 514(7524), 628-632 (2014).
99. Zorde Khvalevsky E, Gabai R, Rachmut IH et al. Mutant KRAS is a druggable target for pancreatic cancer. Proc. Natl Acad. Sci. USA 110(51), 20723-20728 (2013).
100. Bryant KL, Mancias JD, Kimmelman AC, Der CJ. KRAS: feeding pancreatic cancer proliferation. Trends Biochem. Sci. 39(2), 91-100 (2014).
101. Whittle MC, Izeradjene K, Rani PG et al. RUNX3 controls a metastatic switch in pancreatic ductal adenocarcinoma. Cell 161(6), 1345-1360 (2015).
102. Yachida S, Jones S, Bozic I et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467(7319), 1114-1117 (2010).
103. Bobrie A, Colombo M, Krumeich S, Raposo G, Thery C. Diverse subpopulations of vesicles secreted by different intracellular mechanisms are present in exosome preparations obtained by differential ultracentrifugation. J. Extracell. Vesicles doi:10.3402/jev.v1i0.18397 (2012) (Epub ahead of print).
104. Palma J, Yaddanapudi SC, Pigati L et al. MicroRNAs are exported from malignant cells in customized particles. Nucleic Acids Res. 40(18), 9125-9138 (2012).
105. Baranyai T, Herczeg K, Onodi Z et al. Isolation of exosomes from blood plasma: qualitative and quantitative comparison of ultracentrifugation and size exclusion chromatography methods. PLoS ONE 10(12), e0145686 (2015).
106. Romancino DP, Paterniti G, Campos Y et al. Identification and characterization of the nano-sized vesicles released by muscle cells. FEBS Lett. 587(9), 1379-1384 (2013).
107. Chari ST, Kelly K, Hollingsworth MA et al. Early detection of sporadic pancreatic cancer: summative review. Pancreas 44(5), 693-712 (2015).
108. Andea A, Sarkar F, Adsay VN. Clinicopathological correlates of pancreatic intraepithelial neoplasia: A comparative analysis of 82 cases with and 152 cases without pancreatic ductal adenocarcinoma. Mod. Pathol. 16(10), 996-1006 (2003).
109. Luttges J, Reinecke-Luthge A, Mollmann B et al. Duct changes and K-ras mutations in the disease-free pancreas: analysis of type, age relation and spatial distribution. Virchows Arch. 435(5), 461-468 (1999).
110. Tada M, Ohashi M, Shiratori Y et al. Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease. Gastroenterology 110(1), 227-231 (1996).
111. Apte MV, Park S, Phillips PA et al. Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells. Pancreas 29(3), 179-187 (2004).
112. Whatcott CJ, Posner RG, Von Hoff DD, Han H. Desmoplasia and chemoresistance in pancreatic cancer. In: Pancreatic Cancer and Tumor Microenvironment. Grippo PJ, Munshi HG (Eds). Transworld Research Network, Trivandrum, India (2012).
113. Witwer KW, Buzas EI, Bemis LT et al. Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J. Extracell. Vesicles doi:10.3402/jev. v2i0.20360 (2013) (Epub ahead of print).
114. Chari ST, Leibson CL, Rabe KG et al. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology 134(1), 95-101 (2008).
115. Sah RP, Nagpal SJ, Mukhopadhyay D, Chari ST. New insights into pancreatic cancerinduced paraneoplastic diabetes. Nat. Rev. Gastroenterol. Hepatol. 10(7), 423-433 (2013).
116. Pannala R, Leirness JB, Bamlet WR, Basu A, Petersen GM, Chari ST. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology 134(4), 981-987 (2008).
117. Ben Q, Xu M, Ning X et al. Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies. Eur. J. Cancer 47(13), 1928-1937 (2011).
118. Huxley R, Ansary-Moghaddam A, Berrington De Gonzalez A, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: A meta-analysis of 36 studies. Br. J. Cancer 92(11), 2076-2083 (2005).
119. Risch HA, Yu H, Lu L, Kidd MS. Detectable symptomatology preceding the diagnosis of pancreatic cancer and absolute risk of pancreatic cancer diagnosis. Am. J. Epidemiol. 182(1), 26-34 (2015).
120. Aceto N, Bardia A, Miyamoto DT et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell 158(5), 1110-1122 (2014).
121. Lu L, Zeng H, Gu X, Ma W. Circulating tumor cell clusters-associated gene plakoglobin and breast cancer survival. Breast Cancer Res. Treat. 151(3), 491-500 (2015).